give me ppt of total 45-50 slides in clean white slides with introduction about cardioembolic stroke and anticoagulation in stroke of 20slides and 25 slides about CATALYST journal published in lancet
Reading File
Reading File
Searching the Web
CATALYST trial lancet 2026 colchicine anticoagulation stroke cardioembolic
Reading File
Reading Article
Reading Web Page
CATALYST trial DOAC timing stroke atrial fibrillation results
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Running Command
Writing File
Running Command
Running Command
Running Command
Your presentation is ready:
Cardioembolic Stroke CATALYST
Presentation · PPTX
What's inside — 47 slides, clean white design
Design: White backgrounds, navy header bars, gold accent lines, light-blue stat boxes, readable 12-18pt body text. No dark slide backgrounds except section dividers and the conclusion slide.
Section 1: Cardioembolic Stroke & Anticoagulation (Slides 1–20)
| Slide | Content |
|---|---|
| 1 | Title slide |
| 2 | Section divider |
| 3 | What is cardioembolic stroke? |
| 4 | TOAST ischemic stroke classification |
| 5 | High-risk vs moderate-risk cardiac sources (two-column) |
| 6 | AF & stroke — key epidemiological numbers (stat boxes) |
| 7 | Pathophysiology — Virchow's triad, LAA thrombus, embolus path |
| 8 | CHA₂DS₂-VASc score table |
| 9 | Clinical features & investigations (two-column) |
| 10 | Haemorrhagic transformation — ECASS classification |
| 11 | Acute management — tPA, thrombectomy, supportive care |
| 12 | Secondary prevention overview |
| 13 | Warfarin vs DOACs comparison |
| 14 | DOAC selection table (dabigatran, rivaroxaban, apixaban, edoxaban) |
| 15 | Special situations — mechanical valves, LV thrombus, endocarditis |
| 16 | Patent foramen ovale & stroke |
| 17 | The timing dilemma — the 1-3-6-12 day rule explained |
| 18 | The four CATALYST component trials (TIMING, ELAN, OPTIMAS, START) |
| 19 | Why early DOAC? — recurrence risk stat boxes |
| 20 | Bridge slide: "Enter CATALYST" |
Section 2: CATALYST Trial — Lancet 2025 (Slides 21–47)
| Slide | Content |
|---|---|
| 21 | Section divider |
| 22 | Trial overview — full title, journal, PROSPERO, funding |
| 23 | Background & rationale |
| 24 | Search strategy & trial selection criteria |
| 25 | Four component trials — detailed characteristics table |
| 26 | Patient population stat boxes (n=5,441; mean age 77.7y; NIHSS 5) |
| 27 | Early vs delayed arm (two-column) |
| 28 | Primary outcome definition + statistical method |
| 29 | Secondary outcomes list |
| 30 | Primary result — OR 0.70 (CI 0.50–0.98, p=0.039) stat boxes |
| 31 | Recurrent ischaemic stroke — OR 0.66 (p=0.029) |
| 32 | Safety: sICH — OR 1.02 (p=0.96) — no increase |
| 33 | 90-day secondary outcomes table |
| 34 | Subgroup: stroke severity (NIHSS) |
| 35 | Subgroup: infarct size |
| 36 | Why IPD meta-analysis is superior (two-column) |
| 37 | Absolute risk reduction & NNT (~111) |
| 38 | Individual trial results vs CATALYST comparison table |
| 39 | Strengths of CATALYST |
| 40 | Limitations |
| 41 | Clinical implications |
| 42 | Before & after CATALYST practice (two-column) |
| 43 | Full quote from Lancet conclusion |
| 44 | Unanswered questions & future research |
| 45 | Guideline implications post-CATALYST |
| 46 | Complete results summary table |
| 47 | Key takeaways (dark conclusion slide) |
This is a shared conversation. Sign in to Orris to start your own chat.